BioSpace News Archive

CNTX-4975, Centrexion’s Phase 3 ready lead therapy, is a synthetic, ultra-pure injection of trans-capsaicin designed to be injected directly into the painful joint to provide rapid and durable pain relief.

CompleWare and YPrime announce a partnership agreement to deliver enhanced service offerings involving clinical trials, eCOA technology and IRT.

Novoheart announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a three-tiered drug screening system with enhanced capability, sensitivity and accuracy for detecting pharmacological effects on heart contractility that cannot be achieved with conventional models.

Dr. Jeffs brings over 25 years of biopharmaceutical industry experience, including 18 years at United Therapeutics where he retired in 2016 as President and Co-CEO.

The Millar catheter provides an easier way to measure pressures in these patients due to its reduced size and signal accuracy.

GigaGen will use the funds to develop a natural repertoire antibody protein expression system.

PDI announces the appointment of Tom McCurdy as Senior VP and General Manager for its healthcare division and promotes Esperanza Carrion to VP and General Manager of Sani Professional.

CEL-SCI announced today that the outstanding Series S warrants (CUSIP number 150837177) that are publicly traded under the symbol “CVM WS” on the NYSE American have been repriced to $3.00 per share of common stock for a three month period which will end on April 12, 2018.

Funding will expand OWKIN Socrates, the first data driven discovery platform for clinical research.

Siemens Healthineers today laid out its strategy to bolster its market leadership by 2025 and beyond.